A WORLD WITHOUT 1 – FOR A WORLD WITHOUT TYPE 1 DIABETES
INGR1D: early detection of type 1 diabetes risk
Recent studies showed that the harmful immune system response leading to the development of type 1 diabetes often begins in the first months of life in children with an increased genetic risk. Therefore, GPPAD scientists and physicians aim to prevent the development of this immune reaction as early as possible. To achieve this, it is necessary to first identify children at increased genetic risk for type 1 diabetes by investigating certain genes associated with this disease. Studies identifying these children as newborns are available across Europe under different names as part of GPPAD. In the UK, most parents in Oxfordshire, Buckinghamshire and Berkshire can have their children tested free of charge together with the standard newborn screening as part of the INGR1D study.
POInT: Acting preventively
If an increased genetic risk for type 1 diabetes is identified, we will invite parents of the child to take part in the POInT (Primary Oral Insulin Trial) trial. This trial looks at a way to prevent or delay the onset of type 1 diabetes by comparing the daily administration of insulin powder to a placebo in the inhibition or delay of the autoimmune signs that cause the disease. A pilot study has already shown promising results. No side effects have been reported so far.
If treatment with insulin powder should prove to be effective and the development of type 1 diabetes could be prevented, an important and historic milestone will have been reached. Type 1 diabetes could change from a previously unavoidable fate into a disease that could be treated preventively.
In the long term, we want to create a world without type 1 diabetes.
If you would you like to learn more about the risk of type 1 diabetes or preventive treatment visit our FAQs.